Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

被引：28

作者：

Rossi, Ernesto ^{[1
]}

Maiorano, Brigida Anna ^{[1
]}

Pagliara, Monica Maria ^{[2
]}

Sammarco, Maria Grazia ^{[2
]}

Dosa, Tommaso ^{[1
]}

Martini, Maurizio ^{[3
]}

Rindi, Guido ^{[3
]}

Bria, Emilio ^{[1
]}

Blasi, Maria Antonietta ^{[2
]}

Tortora, Giampaolo ^{[1
]}

Schinzari, Giovanni ^{[1
]}

机构：

[1] Fdn Policlin Univ A Gemelli IRCCS, Med Oncol, Rome, Italy

[2] Fdn Policlin Univ A Gemelli IRCCS, Ophtalmol, Rome, Italy

[3] Fdn Policlin Univ A Gemelli IRCCS, Pathol, Rome, Italy

来源：

FRONTIERS IN ONCOLOGY | 2019年 / 9卷

关键词：

BRAF; MEK; target therapy; conjunctival; melanoma; NRAS MUTATIONS; MEK INHIBITION; HARBOR BRAF; SURVIVAL; PHASE-3;

D O I：

10.3389/fonc.2019.00232

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.

引用

页数：5

共 50 条

[41] Retinal Vein Occlusion in a Patient on Dabrafenib and Trametinib Therapy for Metastatic Melanoma
Molero-Senosiain, Mercedes
Salazar, Maria Liseth
Camacho, Irene
Benito-Pascual, Blanca
Valor-Suarez, Clara
CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)
[42] Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)
Massimo Aglietta
Vanna Chiarion-Sileni
Paolo Fava
Massimo Guidoboni
Roberta Depenni
Alessandro Minisini
Francesca Consoli
Paolo Ascierto
Gaetana Rinaldi
Maria Banzi
Riccardo Marconcini
Rossana Gueli
Virginia Ferraresi
Marco Tucci
Giuseppe Tonini
Giovanni Lo Re
Michele Guida
Michele Del Vecchio
Ilaria Gioia Marcon
Paola Queirolo
Targeted Oncology, 2021, 16 : 789 - 799
[43] Tattoo-associated complications of metastatic melanoma treated with dabrafenib and trametinib
Laske, Joerg
Meier, Friedegund
Bauer, Andrea
Beissert, Stefan
Garzarolli, Marlene
MELANOMA RESEARCH, 2018, 28 (05) : 485 - 487
[44] BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer
Falchook, Gerald S.
Millward, Michael
Hong, David
Naing, Aung
Piha-Paul, Sarina
Waguespack, Steven G.
Cabanillas, Maria E.
Sherman, Steven I.
Ma, Bo
Curtis, Martin
Goodman, Vicki
Kurzrock, Razelle
THYROID, 2015, 25 (01) : 71 - 77
[45] A tattoo pigment reaction in a patient with metastatic melanoma treated with dabrafenib and trametinib
Scott, A.
Harris, A.
Thornton, A.
van der Westhuizen, A.
Gillespie, R.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 79 - 79
[46] Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies
Gibney, Geoffrey T.
Zager, Jonathan S.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (07) : 893 - 899
[47] Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
Robert, C.
Grob, J. J.
Stroyakovskiy, D.
Karaszewska, B.
Hauschild, A.
Levchenko, E.
Sileni, V. Chiarion
Schachter, J.
Garbe, C.
Bondarenko, I.
Gogas, H.
Mandala, M.
Haanen, J. B. A. G.
Lebbe, C.
Mackiewicz, A.
Rutkowski, P.
Nathan, P. D.
Ribas, A.
Davies, M. A.
Flaherty, K. T.
Burgess, P.
Tan, M.
Gasal, E.
Voi, M.
Schadendorf, D.
Long, G. V.
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (07): : 626 - 636
[48] Repeated complete response with long-term control of BRAF-mutant melanoma by multiple rechallenges with dabrafenib plus trametinib
Sasaki, Katsuhito
Nakamura, Yasuhiro
Baba, Natsuki
Teramoto, Yukiko
Yamamoto, Akifumi
EUROPEAN JOURNAL OF CANCER, 2020, 139 : 37 - 40
[49] Targeting mutant BRAF in metastatic melanoma
Flemming, Alexandra
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (11) : 842 - 842
[50] Targeting mutant BRAF in metastatic melanoma
Alexandra Flemming
Nature Reviews Drug Discovery, 2010, 9 : 841 - 841

← 1 2 3 4 5 →